Nurix Secures $700M Upfront in $2.3B Roche Collaboration, Shows 83%–93% CLL Response
NRIX•Nurix Therapeutics held $443.5 million cash and pro-forma $1.14 billion liquidity following a Roche collaboration expected to deliver a $700 million upfront and up to $2.3 billion for bexobrutideg. Phase 1a/1b data reported 22.1-month median PFS and response rates of 83%–93% in relapsed/refractory CLL/SLL.
1. Financial Position
Nurix ended Q2 with $443.5 million in cash, cash equivalents and marketable securities and pro-forma liquidity of approximately $1.14 billion including the expected $700 million upfront from Roche. This strengthens its runway for ongoing and planned development programs.
2. Roche Collaboration Terms
Nurix entered a global license and collaboration with Roche for its BTK degrader bexobrutideg, receiving $700 million upfront and eligible for up to $2.3 billion in total payments. They will share development costs 40%/60%, split U.S. profits equally and Nurix will receive tiered royalties on ex-U.S. sales, pending antitrust clearances.
3. Clinical Data Highlights
Updated Phase 1a/1b data in relapsed or refractory CLL/SLL showed a median progression-free survival of 22.1 months with an overall response rate of 83%, and subsequent cohorts reported response rates of 92.9% and 84.2%. The trial included patients with prior BTK inhibitor exposure, high-risk features and central nervous system involvement.
4. Development and Pipeline Expansion
Nurix plans to advance its registrational Phase 2 DAYBreak CLL-201 trial and initiate the Phase 3 DAYBreak CLL-306 study versus pirtobrutinib, alongside exploring bexobrutideg in chronic spontaneous urticaria and multiple sclerosis. Additional combination and earlier-line studies are under preparation to broaden its clinical development footprint.
